Explore

Rapid Read Rapid Read
US Cardiologists Introduce New Guidelines to Transform Cholesterol Prevention

US Cardiologists Introduce New Guidelines to Transform Cholesterol Prevention

Leading cardiologists in the United States have released updated guidelines aimed at transforming the prevention of heart disease by focusing on cholesterol management. These guidelines, presented by the American College of Cardiology and the American Heart Association, emphasize early cholesterol screenings and personalized risk assessments. The new approach encourages doctors to consider individual factors such as age, lifestyle, and family history when assessing a patient's risk of heart disease. The guidelines also highlight the importance of lifestyle changes, including diet, exercise, and smoking cessation, as foundational elements in managing cholesterol levels. This shift towards proactive prevention is expected to reduce the incidence of heart attacks, strokes, and heart failure in the long term.
Rapid Read Rapid Read
New Cholesterol Guidelines by U.S. Cardiologists Aim to Transform Heart Disease Prevention

New Cholesterol Guidelines by U.S. Cardiologists Aim to Transform Heart Disease Prevention

Leading U.S. cardiologists have released new guidelines for managing high cholesterol, emphasizing early screening and proactive prevention to combat heart disease. The guidelines, developed by the American College of Cardiology and the American Heart Association, advocate for earlier interventions and personalized risk assessments. This approach aims to reduce the incidence of heart attacks, strokes, and heart failure by identifying risks at a younger age and recommending lifestyle changes or medications as needed. The guidelines also introduce new methods for calculating heart disease risk, focusing on factors beyond cholesterol levels.
Rapid Read Rapid Read
American Heart Association Issues New Dietary Guidelines, Contradicting Some Trump Administration Recommendations

American Heart Association Issues New Dietary Guidelines, Contradicting Some Trump Administration Recommendations

The American Heart Association (AHA) has released new dietary guidelines that emphasize a diet rich in vegetables, fruits, and whole grains, while prioritizing plant-based proteins over meat. The guidelines suggest limiting sugar, salt, and ultra-processed foods, and recommend replacing full-fat dairy with non-fat and low-fat options. This guidance contrasts with dietary recommendations announced earlier by President Trump, which encouraged the consumption of both animal and plant proteins and full-fat dairy. The AHA's recommendations also include choosing unsaturated fats, avoiding ultra-processed foods, and minimizing added sugars. The organization advises preparing foods with minimal or no salt and limiting alcohol intake. The AHA's guidelines align with the U.S. Food and Drug Administration's dietary guidelines on major issues, and the FDA has expressed a willingness to collaborate with the AHA.
Rapid Read Rapid Read
American Heart Association's Dietary Guidance Contrasts with Federal Recommendations

American Heart Association's Dietary Guidance Contrasts with Federal Recommendations

The American Heart Association (AHA) has issued new dietary guidelines that prioritize plant-based proteins over meat, suggesting a diet rich in vegetables, fruits, and whole grains. This guidance contrasts with federal recommendations, which include the consumption of full-fat dairy and red meat. The AHA advises limiting sugar, salt, and ultra-processed foods, and replacing full-fat dairy with low-fat options. The guidelines also recommend choosing unsaturated fats and minimizing added sugars. The AHA's recommendations align with the US Food and Drug Administration's guidelines on major issues, despite differences with federal dietary advice.
Rapid Read Rapid Read
New Drug Baxdrostat Shows Promise in Reducing Resistant High Blood Pressure

New Drug Baxdrostat Shows Promise in Reducing Resistant High Blood Pressure

A new medication, baxdrostat, has been found to significantly reduce blood pressure in patients whose levels remain high despite taking multiple existing drugs. This discovery comes from a Phase III clinical trial led by Professor Bryan Williams at the UCL Institute of Cardiovascular Science. The trial, known as BaxHTN, involved nearly 800 patients across 214 clinics worldwide and was funded by AstraZeneca. The results, presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine, showed that patients taking baxdrostat experienced an average drop in blood pressure of about 9 to 10 mmHg more than those on a placebo. This reduction is significant enough to lower the risk of cardiovascular events. Baxdrostat works by blocking the production of aldosterone, a hormone that regulates salt and water levels in the body, which in excess can lead to high blood pressure.
Trendline Trendline
Avocado and Mango: A Heart-Healthy Superfood Duo for Daily Diets

Avocado and Mango: A Heart-Healthy Superfood Duo for Daily Diets

Avocado and Mango: A Heart-Healthy Superfood Duo for Daily Diets
Trendline Trendline
Avocado and Mango Combo Shown to Boost Heart Health in New Study

Avocado and Mango Combo Shown to Boost Heart Health in New Study

Avocado and Mango Combo Shown to Boost Heart Health in New Study
Trendline Trendline
Study Reveals Heart Health Benefits of Avocado and Mango Combo for Prediabetics

Study Reveals Heart Health Benefits of Avocado and Mango Combo for Prediabetics

Study Reveals Heart Health Benefits of Avocado and Mango Combo for Prediabetics
Rapid Read Rapid Read
New Blood Pressure Treatment Shows Promise for Resistant Hypertension Patients

New Blood Pressure Treatment Shows Promise for Resistant Hypertension Patients

A new medication, baxdrostat, has demonstrated significant efficacy in reducing blood pressure among patients whose hypertension remains uncontrolled despite existing treatments. This development emerged from a Phase III clinical trial led by Professor Bryan Williams at the UCL Institute of Cardiovascular Science. The trial, known as BaxHTN, involved nearly 800 patients across 214 clinics worldwide and was funded by AstraZeneca. The results, presented at the European Society of Cardiology Congress 2025 and published in the New England Journal of Medicine, revealed that patients taking baxdrostat experienced an average blood pressure reduction of 9 to 10 mmHg more than those on a placebo. Approximately 40% of these patients achieved healthy blood pressure levels, compared to less than 20% in the placebo group. Baxdrostat works by inhibiting the production of aldosterone, a hormone that regulates salt and water levels, thereby addressing a key factor in hypertension.
Rapid Read Rapid Read
Health Experts Warn of Mini Stroke Risks and Symptoms for Early Detection

Health Experts Warn of Mini Stroke Risks and Symptoms for Early Detection

A Transient Ischemic Attack (TIA), commonly known as a 'mini stroke,' is a temporary blockage of blood flow to the brain, often caused by a blood clot or plaque buildup in the arteries. Although symptoms typically resolve quickly, TIAs serve as critical warnings for potential full-blown strokes. According to health experts, recognizing the symptoms early can prevent severe outcomes. Symptoms include sudden loss of balance, vision changes, facial drooping, arm or leg weakness, and slurred speech. The Cleveland Clinic identifies high blood pressure, Type 2 diabetes, and high cholesterol as major risk factors. Other contributing factors include atrial fibrillation, obesity, smoking, alcohol use, and a family history of strokes. TIAs affect at least 240,000 Americans annually, with many cases going unreported due to the transient nature of symptoms.
Trendline Trendline
Pfizer and BioNTech Halt U.S. COVID-19 Vaccine Trial Due to Enrollment Challenges

Pfizer and BioNTech Halt U.S. COVID-19 Vaccine Trial Due to Enrollment Challenges

Pfizer and BioNTech Halt U.S. COVID-19 Vaccine Trial Due to Enrollment Challenges
Rapid Read Rapid Read
Pfizer and BioNTech Halt COVID-19 Vaccine Trial Due to Slow Enrollment

Pfizer and BioNTech Halt COVID-19 Vaccine Trial Due to Slow Enrollment

Pfizer and BioNTech have decided to halt enrollment in a large U.S.-based trial of their updated COVID-19 vaccine due to slow recruitment of participants. The trial aimed to enroll 25,000 to 30,000 healthy adults aged 50 to 64, but enrollment was closed on March 6 after reviewing epidemiological trends. The companies informed trial investigators that surveillance for COVID-19 illness would cease after April 3. The slow enrollment is attributed to the difficulty in recruiting this age group, especially since individuals with chronic conditions like hypertension or diabetes were excluded from the study.